pharmaphorum

JULY 7, 2022

The latest report – in the Wall Street Journal – says that “advanced talks” are underway that could lead to a $200-plus per share offer that would value Seagen at a massive $40 billion, $10 billion more than earlier estimates.

Pharma 52

Pharma Marketing Sales Medicine 52

PM360

APRIL 7, 2023

No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

pharmaphorum

JANUARY 5, 2023

A new operating model for pharma shifted priorities and forced companies to rethink their organisational strategies. Everything from transitioning to virtual meetings with healthcare providers, to navigating the logistics of supply chain disruptions, has permanently altered pharma operations – many would say for the better.

Pharmaceutical 64

Pharmaceutical Recruitment Training Education 64

Pharmaceutical Technology

JANUARY 19, 2023

Antigens such as CD123 and CD33, despite being markers of myeloid cells, are shared with their healthy counterparts, and myeloablation following their depletion often leads to detrimental clinical outcomes. GlobalData’s Pharma Intelligence Center shows 19 autologous CAR-T cell products in Phase I, and nine products in Phase II, globally.

Marketing 52

Marketing FDA Sales Management 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

European Pharmaceutical Review

NOVEMBER 30, 2023

For example, the GMP report stated that the contract development and manufacturing organisation (CDMO) eXmoor pharma, will be launching a cell and gene therapy process development and clinical manufacturing facility in Bristol. Licensing of the manufacturing suites is expected in early 2024.

Manufacturing 74

Manufacturing Recruitment Medicine Biopharma 74

Clarivate

APRIL 18, 2024

In 2023, Humana’s care delivery component CenterWell launched a senior-centered “ Primary Care Anywhere ” program for in-home primary care in Georgia and Louisiana (where Humana leads the MA sectors) and increased senior membership in value-based home care models nationwide to more than 840,000.

Retail 52

Retail Healthcare Healthcare Physicians 52

European Pharmaceutical Review

OCTOBER 12, 2023

AstraZeneca’s facilities in Macclesfield, the UK’s largest pharma manufacturing site, as well as Cambridge, Luton and Speke will all be supplied by energy from the new facility, which is currently being built. Astellas – sustainable innovation September also saw Astellas Pharma Inc. Kerry, Ireland.

Pharmaceutical manufacturing 84

Pharmaceutical manufacturing Manufacturing Pharmaceutical Pharma 84

Clarivate

MAY 13, 2024

In March 2024, New York received approval for a five-year Medicaid expansion through April 1, 2028, extending eligibility to include individuals with incomes up to 250% of the federal poverty level (eligibility was previously capped at 200%). Pillo, Senior Healthcare Research and Data Analyst. The post The U.S.

Insurance 52

Insurance Marketing Healthcare Healthcare 52

pharmaphorum

OCTOBER 10, 2022

As part of efforts to increase uptake of screening programmes, purpose-driven partnerships between the NHS and the pharma industry have emerged as an innovative solution to raise patient awareness. The goal set out by the NHSE Long Term Plan is ambitions: to have three quarters of cancers diagnosed at an early stage by 2028.

Patients 89

Patients Pharma Media Training 89

European Pharmaceutical Review

AUGUST 15, 2022

According to GAVI – the Vaccine Alliance, the drug maker had already agreed to cut its deliveries of rotavirus vaccine by 10 million a year between 2022 and 2028. The pharma giant is not the only company facing challenges in the area, GAVI has also been warned of delays with Bharat Biotech’s rotavirus vaccine, Rotavac.

Manufacturing 84

Manufacturing Pharma Leads Pharmaceutical 84

pharmaphorum

AUGUST 2, 2022

As the technology has developed, the interest from larger pharma companies has continued to grow, resulting in a number of acquisitions and partnerships taking place to gain access to the technology. Looking to the future. billion in revenue last year.

Marketing 91

Marketing Prospecting Sales Pharma 91

Pharmaceutical Technology

FEBRUARY 13, 2023

This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. Non-small cell lung cancer leads as the indication with the highest number of PROTACs in the pipeline, currently sitting at 11 preclinical candidates.

Competition 59

Competition Safety Patients Pharmaceutical 59

pharmaphorum

OCTOBER 18, 2022

Eli Lilly has agreed to buy hearing loss gene therapy developer Akouos in a deal that could value the company at around $610 million – if its lead candidate progresses as hoped in the clinic. per month if conditions are not met, until the end of 2028 when they will all expire. The buyout – for $12.50

Medicine 52

Medicine FDA Patients Pharma 52

World of DTC Marketing

DECEMBER 15, 2021

Together with the growth in wearables—projected to be worth nearly $120 billion by 2028—we are seeing growing democratization of knowledge of one’s own body, with tech enabling consumers to take a more active and regular role in their healthcare. What’s so ironic is that pharma could develop an app to compliment some of their drugs.

Doctors 208

Doctors Medical Patients Marketing 208

Pharmaceutical Technology

DECEMBER 22, 2022

The new joint procedure will launch in Q1 2025 for oncology medicines and other advanced therapy medicinal products and extend to orphan drugs in 2028. Beyond that, they thought the collaboration could lead to mutual learning that could drive positive changes across the continent. Will the joint procedure drive positive change?

Medicine 52

Medicine Pharma Marketing Distribution 52

World of DTC Marketing

JULY 28, 2022

Still, the pharma industry is fighting hard to keep it off the table. Yet, high drug prices lead to soaring out-of-pocket costs , dangerous drug rationing , and a depletion of limited financial resources —especially for those with fixed incomes. Pharma is a very profitable industry. The secretary of the U.S.

Pharma 256

Pharma Prescription Manufacturing Insurance 256

Pharmaceutical Technology

APRIL 27, 2023

When combined with rapid advancement in delivery technologies, mRNA has the potential to lead to breakthroughs in the development of tailored treatment approaches in a wide range of indications from cancer to rare genetic disorders while enabling rapid responses to emerging threats. billion by 2028.

Manufacturing 52

Manufacturing Marketing Medicine Transportation 52